Preliminary Investigation of Beagle Dog as Substitute for Humans in Bioequivalence Studies by Tiwari, Hari Krishan et al.
Tiwari et al 
Trop J Pharm Res 2014;13(3): 383  
 
Tropical Journal of Pharmaceutical Research March 2014; 13 (3): 383-389 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v13i3.11 
Original Research Article 
 
 
Preliminary Investigation of Beagle Dog as Substitute for 
Humans in Bioequivalence Studies  
 
Hari Krishan Tiwari1*, Priya Ranjan Prasad Verma2; Tausif Monif1, Rachna Arora1 
and Simrit Reyar1   
1Department of Clinical Pharmacology and Pharmacokinetics, Ranbaxy Research Laboratories, Plot GP-5, Sec-18, HSIIDC, 
Old Delhi-Gurgaon Road, Gurgaon-122 015, Haryana, 2Birla Institute of Technology, Ranchi, Jharkhand, India. 
 
*For correspondence: Email: hari.tiwari@ranbaxy.com; Tel: + 91-124- 4768051; Fax: +91-124-4231002 
 
Received: 5 December 2013        Revised accepted: 17 January 2014 
 
Abstract 
Purpose: To assess the suitability of beagle dog as an animal model for the evaluation of formulations 
in bioavailability and bioequivalence studies. 
Methods: A generic cetirizine 10 mg tablet formulation was compared with another reference 
formulation using beagle dog as animal model. A crossover oral comparative bioavailability study was 
conducted on cetirizine tablet 10 mg in healthy, male dogs under fasting conditions. The formulations 
were administered orally with the aid of water. Serial blood samples were collected from pre-dose to 
48.0 h post-dose and plasma concentrations of cetirizine were determined using validated liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) analytical method. Pharmacokinetic 
parameters were calculated using non-compartmental analysis while bioavailability was assessed using 
an analysis of variance (ANOVA) model for humans and dogs. 
Results:   Cetirizine plasma concentrations in dog were comparatively higher, in relation to human 
plasma concentrations, due to the smaller blood volume in former. There was a delay in time to reach 
maximum plasma concentration (Tmax) in dog. Cetirizine formulations were found to be bioequivalent in 
either of the species (dog and human). The ratio (test\reference) of least-squares mean for area under 
plasma concentration curve from time zero to last detectable concentration (AUC0-t), area under plasma 
concentration curve extrapolated to infinity (AUC0-∞ ) and maximum plasma concentration (Cmax), 
calculated for the dogs were comparable to those for humans. AUC0-t, AUC0-∞ and Cmax ratios ranged 
within 92.81 - 106.80 % for dogs and 95.43 – 104.84 % for humans  
Conclusion:  The results suggest that beagle dogs can be used in place of humans in bioequivalence 
tests on generic products of cetirizine. 
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Cetirizine is a selective H1 receptor inverse 
agonist used in the treatment of allergies, hay 
fever, angioedema, and urticaria. Generic drug 
companies have played a significant role in the 
developing world by supplying cost-effective 
treatment regimens [1]. To make cost effective 
formulation, initial development of formulations 
can be feasible using animal model. This can 
serve as guideline for planning clinical 
bioequivalence studies. The dog model is used 
frequently in formulation development and has 
shown utility for prediction of human 
bioavailability [2, 3]. During initial phase of 
formulation development, multiple formulations 
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would require to be screened out to match with 
reference formulation in terms of rate and extent 
of absorption. The current study was planned to 
evaluate suitability of using beagle dog as an 
animal model to screen out the prototype under 
development closer to reference product in terms 
of bioavailability. This provides an additional 
advantage in terms of cost benefit, faster 
execution of study and it would also results in 
faster formulation development process. Kevin et 
al  performed bioavailability studies for ritonavir 
formulations in which 12 out of 16 experimental 
ritonavir formulations in dog mirrored those 
obtained in human (both bioequivalent and non-
bioequivalent results) [4]. 
 
Cetirizine is well-tolerated in dogs [5]. In this 
study, we assessed and compared the relative 
bioavailability of generic cetirizine 10 mg tablet 
manufactured by Ranbaxy Laboratories Limited 
with that of innovator product Zyrtec 10 mg tablet 
(containing cetirizine) manufactured by UCB 






The test formulation was generic cetirizine 10 mg 
tablet (batch no.1962123) manufactured by 
Ranbaxy Laboratories Limited, India, and 
reference formulation was innovator product 
Zyrtec 10 mg tablet (containing cetirizine 10 mg, 
batch no.08C26C), manufactured by UCB 
Farchim SA, Switzerland. These were used for 
bioequivalence study in beagle dogs and 
humans. 
 
Subjects and criteria 
 
A  total of 12 adult male healthy dogs aged 37 - 
54 months with body weight ranging from 10 - 16 
kg (Source: Animal Breeding and Housing 
Facility, Ranbaxy Research Laboratories, 
Gurgaon, India) were  received  for study. Each 
animal was housed in individual pen. 
Temperature and relative humidity were 
maintained at 18 – 29 oC and 30 – 70 %, 
respectively. Illumination was controlled to give 
approximately a sequence of 14 h light and 10 h 
dark. Air changes of Kennel Facility were 
maintained at or above 12 air changes/hour. The 
tablets were administered orally.  Approximately 
10 ml of water was administered after dosing. 
Animals were divided into two groups (Group I 
and Group II), comprising of six animals each. 
Group I received cetirizine tablet 10 mg, a test 
formulation (T) and Group II received zyrtec 10 
mg tablet, a reference formulation (R). After six 
days washout period, Group I administered orally 
with Zyrtec 10 mg tablet and Group II with 
cetirizine tablet 10 mg.  
 
Twenty four healthy, adult, male, Indian Asian 
human subjects aged 19-35 year were used. 
Body weight was ranging from 48-84 kg. The 
subjects were admitted 12 h before dose 
administration in each period. The tablets were 
administered orally and the subjects were 
randomized to receive a single oral dose of test 





This trial was a single-center, two-way crossover 
study designed to assess the bioavailability of 
cetirizine 10 mg tablet and Zyrtec 10 mg tablet 
under fasting conditions in beagle dogs. 
Treatments were administered with 
approximately 10 mL of water and separated by 
adequate washout period (6 days). The dogs 
were fed 200 - 250 g/day of standard pelleted 
meal (Pedigree adult dog feed, Mars Pvt Ltd, 
India). Food was withdrawn at least 10 h prior to 
commencement of dosing and up to 
approximately 3 h post dose. Water was 
restricted to 1 h pre-dose to 2 h post-dose. 
 
The study was performed as per in-house 
standard operating procedures based upon the 
guidelines [6,7], recommendations of FELASA 
[8], the Committee for the Purpose of Control and 
Supervision of Experiments on Animals 
(CPCSEA) guidelines for Laboratory Animal 
Facility [9], Guide for the Care and Use of 
Laboratory Animals [10]. Ethical approval was 
obtained from Institutional Animal Ethics 
Committee (IAEC protocol no 21/2010), which is 
monitored by CPCSEA under Ministry of 
Environment and Forest, Government of India. 
 
Healthy, adult, male, human subjects aged 19-35 
year were used. A bioavailability study in twenty 
four Asians was conducted as per the basic 
principles defined in US 21 CFR part 320. Ethical 
approval was obtained for protocol no. BE-212-
CETI-2008 from Sentinel Independent Ethics 
Committee, India. Informed consent was 
obtained from subjects. This study was 
performed as per the principles enunciated in the 
Declaration of Helsinki. This study was 
conducted by Ranbaxy Laboratories Limited, 
India and the data were used for comparison with 
dog study data. An open label, balanced, 
randomized, two-treatment, two-sequence, two-
period, single-dose, cross-over design was used. 
A single oral dose of test formulation or reference 
formulation of cetirizine was administered with 
240 mL of drinking water at ambient temperature 
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after an overnight fast of at least 10 h. Each 
treatment was separated by a washout period of 
eleven days. 
 
Bioavailability study in animals 
 
Twelve dogs were taken for the study and all of 
them completed the study. Formulations were 
administered through mouth (oral route).  
Approximately 10 ml of water was administered 
after dosing. Animals were divided into two 
groups (Group I and Group II), comprising of six 
animals each. Group I received cetirizine tablet 
10 mg, a test formulation (T) and Group II 
received zyrtec 10 mg tablet, a reference 
formulation (R). After six days wash out period, 
Group I administered with zyrtec 10 mg tablet 
and Group II with cetirizine tablet 10 mg.Blood 
samples approximately 0.8 ml were collected 
from cephalic / saphenous vein in labeled tubes 
containing anticoagulant 1.8 mg/ml of EDTA 
(K3), predose, and at 0.167, 0.500, 0.833, 1.000, 
1.333, 1.667, 2.000, 2.500, 3.000, 4.000, 6.000, 
8.000, 12.000, 24.000, 36.000 and 48.000 h post 
dose.  Plasma (approximately 300 µl) was 
separated by centrifugation at 3500 rpm for 10 
minutes at 4°C (+ 2°C) and stored in a freezer 
(below -20 C).  
 
The plasma samples were analyzed by a 
validated method based on the Food and Drug 
Administration validation guidelines [11]. The 
plasma concentrations of cetirizine were 
determined using high-performance liquid 
chromatography fitted with mass spectrometry 
(LC-MS/MS) detection. Cetirizine and the internal 
standard (fexofenadine) were extracted from 
plasma using solid-phase extraction. Internal 
standard working solution (50 µL) was added to 
100 µL of each plasma sample and vortexed. 
The samples were transferred to pre-conditioned 
Oasis HLB (30 mg/cc) extraction cartridges. 
Analyte was eluted from cartridge with 1 mL 
methanol twice. Extract was evaporated and 
reconstituted with 200 µL mobile phase 
{acetonitrile : 10 mM ammonium formate buffer 
pH 3.5 (90:10 V/V)}. The extracts were injected 
into the LC-MS/MS system, and positive ions 
were monitored in multiple reaction monitoring 
(MRM) mode. The ion transitions (m/z) 
389.4/201.3 and 502.5/466.5 were monitored for 
cetirizine and internal standard, respectively. 
Instrument setup consisted of an autosampler, 
an API 3000 detector and a data-processing 
system (Analyst 1.4.1). Linearity of cetirizine was 
assessed by plotting area ratios versus standard 
concentrations and using a linear regression 
weighted 1/cetirizine concentration. Validated 
analytical range for cetirizine in plasma was 4.94 
- 811.99 ng/mL. Inter batch precision (CV %) was 
≤9.9% and accuracy (% theoretical) ranged 
between 95.8 and 106.2 % at low, medium and 
high quality control levels. 
 
Bioavailability study in human 
 
Twenty-two human volunteers completed the 
study. Two human subjects were withdrawn from 
study. A single oral dose of test formulation 
(Cetirizine Hydrochloride 10 mg tablets) or 
reference formulation (Zyrtec® 10 mg tablets) 
was administered with 240 mL of drinking water 
after an overnight fast of at least 10 hrs.  
Subjects received alternate treatment in the 
subsequent period in such a way that each 
subject received both the treatments at the end 
of the study. 
 
 Blood samples were collected at pre-dose and 
at 0.167, 0.333, 0.500, 0.667, 0.833, 1.000, 
1.250, 1.500, 1.750, 2.000, 2.500, 3.000, 4.000, 
5.000, 6.000, 8.000, 10.000, 12.000, 16.000, 
20.000, 24.000, 35.000 and 47.000 h post-dose 
in each period. High performance liquid 
chromatography using mass spectrometric 
detection method was used to determine 
cetirizine content in human plasma.  
 
Human plasma samples were analyzed by a 
validated method based on the Food and Drug 
Administration validation guideline [11]. The 
plasma concentrations of cetirizine were 
determined using high-performance liquid 
chromatography fitted with mass spectrometry 
(LC-MS/MS) detection. Cetirizine and the internal 
standard (diclofenac) were extracted from 
plasma using solid-phase extraction. Internal 
standard working solution (50 µL) was added to 
200 µL of each plasma sample and vortexed. 
Samples were transferred to pre-conditioned 
HLB (30 mg/cc) extraction cartridges. The 
analyte was eluted from the cartridge with 1 mL 
methanol followed by 1 mL of water twice. The 
extract was evaporated and reconstituted with 
500 µL mobile phase {methanol : 2 mM 
ammonium acetate solution : acetic acid 
(80:20:0.02 V/V/V)}. The extracts were injected 
into the LC-MS/MS system, and positive ions 
were monitored in multiple reaction monitoring 
(MRM) mode. The ion transitions (m/z) 
389.1/201.0 and 296.0/250.0 were monitored for 
cetirizine and internal standard, respectively. 
Instrument setup consisted of an autosampler, 
an API 3000 detector and a data-processing 
system (Analyst 1.4.1). The linearity of cetirizine 
was assessed by plotting area ratios versus 
standard concentrations and using a linear 
regression weighted 1/ cetirizine2 concentration. 
Validated analytical range for cetirizine in plasma 
was 5.00-697.21 ng/mL. Inter batch precision 
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(CV %) was ≤ 9.0 % and accuracy (% 
theoretical) ranged between 94.4 and 98.8 % at 




Non-compartmental analysis for deriving 
pharmacokinetic parameters was performed with 
WinNonlin version 5.0.1 (PharSight Corporation, 
Mountain View, California) on both the species 
concentration data. Actual time of sample 
collection was used for pharmacokinetic analysis 
of cetirizine. AUC from time 0 to the time for the 
last measurable concentration (AUC0–t) was 
calculated by linear trapezoidal method. AUC 
from time 0 to infinity (AUC0–∞) was calculated as 
the sum of AUC0–t and ratio of last measurable 
plasma concentration to elimination rate 
constant. Cmax was calculated as the maximum 
measured plasma concentration over the time 
span specified. Tmax was calculated as time of 
maximum measured plasma concentration. 
 
Statistical analysis  
 
Statistical analysis was performed using 
Statistical Analysis System software (SAS) 
version 9.1. Analysis of variance (ANOVA) was 
performed on the log natural (ln)-transformed 
pharmacokinetic parameters Cmax, AUC0–t and 
AUC0–∞ using Type III sum of squares, with the 
main effects of formulation, period, sequence 
and animal /subject nested within sequence. 
Sequence effect, if any, was tested at the 10 % 
level of significance using the animal / subject 
nested within sequence mean square as error 
term. Formulation and period effects were tested 
at 5% level of significance against the residual 
error (mean square error) from the ANOVA 
model as error term. Each ANOVA included 
calculation of least-squares means (LSMs), the 
difference between the adjusted formulation 
means and the standard error associated with 
the difference. 
 
Ratio of test (T) and reference (R) formulation 
least square means were calculated for log-
transformed pharmacokinetic parameters (AUC0-
t, AUC0-∞ and Cmax).  It was expressed as a LSM 
percentage of the reference formulation. 90% 
confidence intervals for the ratio of LSMs were 
also calculated for cetirizine using two one sided 
hypothesis at 5 % level of significance.   
 
Test and reference formulation ratio for Cmax, 
AUC0–t and AUC0–∞ for both species were 
compared statistically using the parametric t-test 
at 5 % level of significance. Formulations were 
considered bioequivalent if 90 % confidence 
intervals (CIs) and ratios were within the 





Pharmacokinetics and statistics 
 
 For the beagle dogs, the arithmetic mean ± (SD) 
values for Tmax, Cmax AUC0–t and AUC0–∞  for test 
(T) and reference (R) formulations, respectively, 
were as follows: 1.8 (0.67) h and 1.9 (0.79) h; 
4037.68 (527.94) and 4069.04 (621.43) ng/mL; 
54532.64 (15110.48) and 55492.52 (15497.44) 
ng.h/mL; 61831.85 (18569.05) and 62473.60 
(19254.01) ng.h/mL in dog study. The AUC 
extrapolated observed was < 20 % in all cases 
expect one, which implies that the sampling 
scheme was adequate for characterization of 
pharmacokinetic profile. 
 
Point values of test/reference mean ratio for Cmax, 
AUC0-t and AUC0–∞were 99.56, 98.20 and 99.17 
% in the dog study. The 90 % CIs of ratios were 
within the acceptance limits of 80-125% for 
cetirizine dog study. Least square mean values, 
ratios and 90% CIs for pharmacokinetic variables 
obtained from this study are summarized in 
Table 1.  
 
Table 1: Least square mean values, ratios and 90 % 
CIs for pharmacokinetic variables of cetirizine 































Mean dog plasma cetirizine concentrations are 
represented in Figure 1. This showed that both 
formulations exhibit identical pharmacokinetic 
profile and it indicates that both formulations are 
similar in terms of rate and extent of absorption. 
 
Pharmacokinetic and statistical analyses were 
performed on data from 22 human subjects for 
cetirizine. Pharmacokinetic parameters were 
calculated and thereafter these were subjected to 
statistical analysis.  The arithmetic mean (SD) 
values for Tmax, Cmax AUC0–t and AUC0–∞ for 
Tiwari et al 





Figure 1: Linear plot of mean dog plasma cetirizine 
concentration (ng/mL) versus time (h) of test (□) and 




Figure 2: Linear plot of mean human plasma cetirizine 
concentration (ng/mL) versus time (h) of test (□) and 
reference (∆) formulations 
 
cetirizine and zyrtec formulations, respectively, 
were as follows: 1.1 (0.41)and 0.9 (0.43) h, 230.9 
(52.53) and 228.71 (42.17) ng/mL, 2016.29 
(515.37) and 2018.09 (522.42) ng.h/mL; 2140.26 
(538.20) and 2143.68 (537.93) ng.h/mL in human 
study. AUC% extrap observed was < 20 % in all 
cases for cetirizine, which implied that sampling 
scheme, was adequate for characterization of 
pharmacokinetic profile. The ratios of test (T) and 
reference (R) formulations LSMs for Cmax, AUC0-t 
and AUC0–∞ were 100.02, 99.99 and 99.82 % in 
human study. The 90 % CIs for ratios were within 
the acceptance limits of 80 – 125 % for cetirizine 
human study. Least square mean values, ratios 
and 90 % CIs for pharmacokinetic variables 
obtained from human study are summarized in 
Table 2.  
 
Mean human plasma cetirizine concentrations 
are represented in Figure 2.  This showed that 
both formulations exhibit identical 
pharmacokinetic profile and it indicates that both 
formulations are similar in terms of rate and 
extent of absorption. 
 
A parametric t-test was performed using SAS 
software at 5 % level of significance (With PROC 
T-TEST) on T/R ratio of Cmax, AUC0–t and AUC0–∞ 
of both the species (dog and human) and no 
statistically significant difference was observed. 
Table 3 represents the p-value observed for 
pharmacokinetic parameters with equal and 
unequal variance assumption. A p value > 0.05 





The higher Cmax in dogs compared to humans is 
more likely due to smaller blood volume in dogs. 
Certain other factors might be accounted like 
high destructive mechanical forces in dogs [12], 
different enzyme content of gut. Further, 
cetirizine is a BCS class I molecule with high 
solubility and high permeability. Tmax was 1.8 
(0.67) and 1.9 (0.79) h for test and reference 
formulations in dog. Tmax was 1.1 (0.41) and 0.9 
(0.43) h for test and reference formulations in 
human, respectively. It shows delayed Tmax in 
dog.  This shows that cetirizine was absorbed 
with a Tmax around 2 h in dog as compared to 
human which was around 1 h.  
 
Based on the ANOVA results from dog, no 
significant formulation, period and sequence 
effect was observed for log transformed PK 
parameters Cmax, AUC0-t and AUC0- at 5 % level 
of significance. No statistically significant 
difference was observed in Test/Reference ratio 
of Cmax, AUC0–t and AUC0–∞ of both species at 5 
% level of significance.  
 
Table 2: Least square mean values, ratios and 90 % CIs for pharmacokinetic variables of Cetirizine 
formulations in humans 
Parameter  
Treatment Ratio of LSM 
Cetirizine Zyrtec T/R (90% CIs) %CV 
Tablet (T) Tablet (R) 
 AUC0–∞ (ng.h/mL) 2077.13 2080.79 99.82 (96.84–102.90) 6.3 
AUC0-t  (ng.h/mL) 1954.39 1954.63 99.99 (96.57–103.53)  6.0 
Cmax (ng/mL) 225.30 225.26 100.02 (95.43–104.84) 9.5 
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Table 3: Results of t-test for pharmacokinetic parameters 
 
Variable Method Variance t -value P-value* > |t| 
Ratio_ Cmax Pooled Equal -0.12 0.9088 
Ratio_ Cmax Satterthwaite Unequal -0.12 0.9069 
Ratio_ AUC0–t Pooled Equal -0.59 0.5606 
Ratio_ AUC0–t Satterthwaite Unequal -0.62 0.5429 
Ratio_ AUC0–∞ Pooled Equal -0.25 0.8063 
Ratio_ AUC0–∞ Satterthwaite Unequal -0.25 0.8088 
* Significantly different (if p < 0.05) 
 
 Comparison of least square means ratios across 
beagle dog and human bioavailability study had 
showed < 2 % variation in least square means 
ratios (T/R) of Cmax and AUC in dog and human 
data. This indicates that least square means 
ratios (test/reference) dog and human are 
comparable to each other. Similar intra-subject 
variability observed for primary pharmacokinetic 
parameters in dog and human bioavailability 
studies. The intra-subject variability (%CV) of 
Cmax and AUC are approximately 9% and 6%, 
respectively. This exhibits that formulation 
variability, i.e., intra-subject variability will remain 
the same whether bioavailability study conducted 
on dog or human.   
 
Outcome of bioequivalence study is depended 
upon ratio and 90 % CI for primary 
pharmacokinetic parameter such as Cmax and 
AUC. Even though differences were observed in 
pharmacokinetic values as discussed above but 
there is no significant differences were observed 
on absolute T/R ratio and intra-subject variability. 
The 90 % CI for ratios were within the 
acceptance limits of 80 - 125 % for cetirizine dog 
study as well as human study. The products 





The results of the preliminary investigation 
suggest that beagle dogs may be suitably 
substituted for human subjects in the 
bioequivalence studies of generic products with 
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